These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Use of ATG for reversal of acute allograft rejection. Nowygrod R; Appel G; Hardy MA Transplant Proc; 1981 Mar; 13(1 Pt 1):469-72. PubMed ID: 7022875 [No Abstract] [Full Text] [Related]
3. [Clinical significance of immunological findings for the survival time of kidney transplants with antilymphocyte globulin therapy]. Bullinger W; Hammer C; Land W; Welter H Chir Forum Exp Klin Forsch; 1979; ():319-24. PubMed ID: 378592 [TBL] [Abstract][Full Text] [Related]
4. In vivo - in vitro correlates of antithymocyte globulin (ATG) immunosuppression in the human. Thomas F; Berry R; Mendez-Picon G; Thomas J; Lower RR; Lee HM Proc Clin Dial Transplant Forum; 1978 Nov 18-20; 8():56-61. PubMed ID: 386321 [No Abstract] [Full Text] [Related]
5. The use of antilymphoblast globulin in the treatment of renal allograft rejection. Howard RJ; Condie RM; Sutherland DE; Simmons RL; Najarian JS Transplant Proc; 1981 Mar; 13(1 Pt 1):473-4. PubMed ID: 7022876 [No Abstract] [Full Text] [Related]
6. Antithymocyte globulin as the primary treatment for renal allograft rejection. Nelson PW; Cosimi AB; Delmonico FL; Rubin RH; Tolkoff-Rubin NE; Fang L; Russell PS Transplantation; 1983 Nov; 36(5):587-9. PubMed ID: 6356523 [No Abstract] [Full Text] [Related]
7. OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A. Widmer U; Frei D; Keusch G; Burger HR; Largiader F; Binswanger U Transplant Proc; 1988 Oct; 20(5 Suppl 6):90-5. PubMed ID: 3140454 [No Abstract] [Full Text] [Related]
8. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection. Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569 [TBL] [Abstract][Full Text] [Related]
9. [Immunosuppression by means of antilymphocyte serums in humans]. Revillard JP Nouv Rev Fr Hematol; 1972; 12(2):129-37. PubMed ID: 4264610 [No Abstract] [Full Text] [Related]
10. The combined use of antilymphocyte serum and cyclophosphamide to suppress renal allograft rejection in the rat. Winearls CG; Fabre JW; Millard PR; Morris PJ Clin Exp Immunol; 1979 Feb; 35(2):242-9. PubMed ID: 373937 [TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple rejection episodes with ALG or ATGAM after cadaveric renal transplantation. Toledo-Pereya LH; Whitten J; Baskin S; McNichol L; Thavarajah K; Lin W Bol Asoc Med P R; 1984 Jul; 76(7):293-6. PubMed ID: 6383417 [No Abstract] [Full Text] [Related]
12. [Lymphocytic molecules implicated in rosette phenomenon. Differential effect of antilymphocyte serum on T (CD2+E2+) and B (CD2-E2+) lymphocytes]. Ticchioni M; Bernard-Pomier G; Cassuto-Viguier E; Zoccola D; Allieri-Rosenthal MA; Vivinus M; Bernard A Therapie; 1992; 47(4):293-6. PubMed ID: 1494790 [TBL] [Abstract][Full Text] [Related]
13. Intravenous antilymphocyte globulin in human cadaveric renal allotransplantation. Clinical and immunologic observations. Collste LG Acta Chir Scand; 1972; 138(8):765-74. PubMed ID: 4565721 [No Abstract] [Full Text] [Related]
14. Clinical uses of anti-thymocyte globulin (ATGAM), Part I. Gilbert C N C Med J; 1984 Nov; 45(11):737-9. PubMed ID: 6392893 [No Abstract] [Full Text] [Related]
15. Nonsteroid treatment of rejection in kidney transplantation. A new approach including long-term treatment of rejection with antilymphoblast globulin in a high risk population. Toledo-Pereyra LH; Mittal VK; Baskin S; McNichol LJ; Whitten JI Transplantation; 1982 Mar; 33(3):325-7. PubMed ID: 6801834 [No Abstract] [Full Text] [Related]
16. Does suppression of T-RFC determine in vivo immunosuppressive effect of ATG? Geis WP; Giacchino JL; Buckingham JM; Bansal VK; Iwatsuki S; Kerman RH; Ing TS; Hano JE Transplant Proc; 1979 Jun; 11(2):1433-4. PubMed ID: 382533 [No Abstract] [Full Text] [Related]